scholarly journals High Incidence of Osteoporosis in a Natural History Cohort of Patients with Moderate to Severe Chronic Graft-Versus-Host Disease and Risk Factor Analysis

2015 ◽  
Vol 21 (2) ◽  
pp. S77
Author(s):  
Filip Pirsl ◽  
Lauren M. Curtis ◽  
Seth M. Steinberg ◽  
Masenjka Katic ◽  
Marnie Dobbin ◽  
...  
Keyword(s):  
Factor Analysis ◽  
Risk Factor ◽  
Natural History ◽  
Graft Versus Host Disease ◽  
Risk Factor Analysis ◽  
Host Disease ◽  
Graft Versus Host ◽  
High Incidence

scholarly journals Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease

2016 ◽  
Vol 22 (8) ◽  
pp. 1517-1524 ◽  
Author(s):  
Filip Pirsl ◽  
Lauren M. Curtis ◽  
Seth M. Steinberg ◽  
Sri Harsha Tella ◽  
Mašenjka Katić ◽  
...  
Keyword(s):  
Factor Analysis ◽  
Risk Factor ◽  
Graft Versus Host Disease ◽  
Large Cohort ◽  
Risk Factor Analysis ◽  
Host Disease ◽  
Graft Versus Host

scholarly journals Thalidomide as salvage therapy for chronic graft-versus-host disease

Blood ◽  
1995 ◽  
Vol 86 (9) ◽  
pp. 3604-3609 ◽  
Author(s):  
PM Parker ◽  
N Chao ◽  
A Nademanee ◽  
MR O'Donnell ◽  
GM Schmidt ◽  
...  
Keyword(s):  
Side Effects ◽  
Complete Remission ◽  
Graft Versus Host Disease ◽  
Dose Intensity ◽  
Drug Discontinuation ◽  
Effective Agent ◽  
Host Disease ◽  
Graft Versus Host ◽  
Number Of Patients ◽  
High Incidence

Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD). To determine the efficacy of this agent in patients with refractory CGVHD a total of 80 patients who failed to respond to prednisone (PSE) or PSE and cyclosporine (CSA) were treated with thalidomide. Sixteen patients (20%) had a sustained response, 9 with a complete remission and 7 with a partial response. Twenty-nine patients (36%) had thalidomide discontinued because of side effects, which included sedation, constipation, neuritis, skin rash, and neutropenia. Side effects were reversible with drug discontinuation except for mild residual neuritis in one case. Rashes and neutropenia have not previously been reported as thalidomide side effects when used for CGVHD treatment. We conclude thalidomide is immunosuppressive and active in the treatment of CGVHD. A high incidence of reversible side effects limited dose intensity and reduced the number of patients who could benefit from treatment.

scholarly journals Lactose drives Enterococcus expansion to promote graft-versus-host disease

Science ◽  
2019 ◽  
Vol 366 (6469) ◽  
pp. 1143-1149 ◽  
Author(s):  
C. K. Stein-Thoeringer ◽  
K. B. Nichols ◽  
A. Lazrak ◽  
M. D. Docampo ◽  
A. E. Slingerland ◽  
...  
Keyword(s):  
Gastrointestinal Tract ◽  
Microbial Communities ◽  
Graft Versus Host Disease ◽  
Inflammatory Disease ◽  
Hematopoietic Cell Transplantation ◽  
Commensal Bacterium ◽  
Host Disease ◽  
Graft Versus Host ◽  
Systemic Inflammatory Disease ◽  
High Incidence

Disruption of intestinal microbial communities appears to underlie many human illnesses, but the mechanisms that promote this dysbiosis and its adverse consequences are poorly understood. In patients who received allogeneic hematopoietic cell transplantation (allo-HCT), we describe a high incidence of enterococcal expansion, which was associated with graft-versus-host disease (GVHD) and mortality. We found that Enterococcus also expands in the mouse gastrointestinal tract after allo-HCT and exacerbates disease severity in gnotobiotic models. Enterococcus growth is dependent on the disaccharide lactose, and dietary lactose depletion attenuates Enterococcus outgrowth and reduces the severity of GVHD in mice. Allo-HCT patients carrying lactose-nonabsorber genotypes showed compromised clearance of postantibiotic Enterococcus domination. We report lactose as a common nutrient that drives expansion of a commensal bacterium that exacerbates an intestinal and systemic inflammatory disease.

High incidence of urinary tract infections after photoselective laser vaporisation of the prostate: a risk factor analysis of 665 patients

2019 ◽  
Vol 38 (7) ◽  
pp. 1787-1794
Author(s):  
Kathrin Bausch ◽  
Jürg Motzer ◽  
Jan A. Roth ◽  
Marc Dangel ◽  
Hans-Helge Seifert ◽  
...  
Keyword(s):  
Factor Analysis ◽  
Risk Factor ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Risk Factor Analysis ◽  
High Incidence ◽  
Tract Infections ◽  
Laser Vaporisation

Periodontal disease might be a risk factor for graft versus host disease. A systematic review

2020 ◽  
Vol 147 ◽  
pp. 102878 ◽  
Author(s):  
Alexandru Mester ◽  
Alexandra Iulia Irimie ◽  
Alina Tanase ◽  
Sebastian Tranca ◽  
Radu Septimiu Campian ◽  
...  
Keyword(s):  
Systematic Review ◽  
Risk Factor ◽  
Periodontal Disease ◽  
Graft Versus Host Disease ◽  
Host Disease ◽  
Graft Versus Host

Risk Factor Analysis for Predicting Chronic Graft-Versus-Host Disease of Progressive or Quiescent Type in a Cohort of Patients with a History of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5337-5337
Author(s):  
Sang Kyun Sohn ◽  
Dong Hwan Kim ◽  
Jin Ho Baek ◽  
Jong Gwang Kim ◽  
Kyu Bo Lee ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Graft Versus Host Disease ◽  
Acute Gvhd ◽  
Clinical Parameters ◽  
Host Disease ◽  
Graft Versus Host ◽  
History Of

Abstract Background: As a series of our previous investigation (Haematologica, 2005. 90: 939–48) identifying poor prognostic factors (lymphocytopenia and visceral involvement) at the onset of acute GVHD (aGVHD) in patients with a history of aGVHD after allogeneic stem cell transplantation (SCT), we tried to identify variables that could predict the development of chronic GVHD of progressive or quiescent type (pq cGVHD) and patients’ outcome after the diagnosis of cGVHD in cohort of 99 patients who experienced aGVHD after allogeneic SCT. Patients and Methods: We evaluated the risk factors for cGVHD of pq cGVHD with various clinical parameters in patient group with a history of aGVHD and also the prognostic significance of various clinical parameters at diagnosis of cGVHD to determine the prognostic factor for GVHD-specific survival (GSS) in patients with pq cGVHD. Results: From 118 patient experienced aGVHD of any degree, 99 patients were evaluated for cGVHD. The cumulative incidence of overall and extensive pq cGVHD at 2 years was estimated as 84.4% and 63.1%, respectively. In univariate analyses for risk factors of pq cGVHD, severe grade 3,4 aGVHD, primary treatment failure (PTF), lymphocytopenia (≤100/μl), elevated ALP (>160IU/l), visceral involvement, hepatic or gut involvement were identified. Especially, severe aGVHD (p=0.022 and <0.001), PTF (p=0.009 and 0.010) for overall and extensive pq cGVHD, lymphocytopenia (p=0.031) for extensive pq cGVHD, and elevated ALP (p=0.001) for overall pq cGVHD were independent risk factors. The prediction model of subsequent pq cGVHD validated these risk factors with respect to the incidences of overall pq cGVHD (48.6% versus 91.9% for no risk factor versus 1~3 risk factor(s)) and of extensive pq cGVHD (34.2% versus 59.6% versus 92.2% for no / 1 / 2~3 risk factors). HLA-disparity and stem cell source did not influence on the development of pq cGVHD in this cohort. The GSS and probability of systemic immunosuppressive treatment at 2 year after diagnosis of cGVHD was estimated as 55.9% and 51.9%. The GSS was significantly associated with the performance status (p=0.004) and lymphocytopenia (≤ 1,000/μl, p=0.022) at diagnosis of cGVHD by Cox’s proportional hazard model. Conclusion: Severe aGVHD, PTF, lymphocytopenia and elevated ALP may be useful predictive factors for the development of pq cGVHD in a cohort of patients who experienced a GVHD after allogeneic SCT. Figure. The significance of the predictive model for the development of overall (A) or extensive chronic graft-versus-host disease (GVHD; B) after occurence of acute GVHD Figure. The significance of the predictive model for the development of overall (A) or extensive chronic graft-versus-host disease (GVHD; B) after occurence of acute GVHD

Sign in / Sign up

Export Citation Format

Share Document